The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

The Food and Drug Administration (FDA ... T2D and established CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease. Kroger is cutting about 200 employees ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

Of lately weight loss drugs have been making the headlines, not because of the benefits they offer, including curbing ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...